Nathan P. Lawrence
Geen lopende functies
Vermogen: 44 $ op 30-04-2024
Profiel
Nathan P.
Lawrence worked as a Director of Research & Development at Boston Biomedical, Inc. and as a Vice President of Sales & Marketing at Pressure BioSciences, Inc. Lawrence holds a doctorate degree from Yale University, a graduate degree from Southern Connecticut State University, and an undergraduate degree from the University of Miami.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
06-07-2012 | 200 ( 0.14% ) | 44 $ | 30-04-2024 |
Eerdere bekende functies van Nathan P. Lawrence
Bedrijven | Functie | Einde |
---|---|---|
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Hoofd Techniek/Wetenschap/O&O | - |
PRESSURE BIOSCIENCES, INC. | Verkoop & Marketing | - |
Opleiding van Nathan P. Lawrence
University of Miami | Undergraduate Degree |
Southern Connecticut State University | Graduate Degree |
Yale University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
PRESSURE BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |